OKN-007 Development Stage

Glioblastoma Multiforme (GBM)

  • Ph 1b completed with 18 recurrent GBM patients in monotherapy
  • Ph 2 trial for recurrent GBM patients ongoing, a combination therapy with Temozolomide (TMZ)
  • Ph 1 trial for naïve GBM patients ongoing, a combination therapy with radiation and TMZ
  • Ph1b trial with oral dose of OKN-007 for recurrent GBM patients ongoing

Diffuse Intrinsic Pontine Glioma (DIPG), an ultra-rare pediatric disease

  • DIPG has very grim prognosis with median survival less than 1 year. No approved therapeutic available.
  • Oblato received Rare Pediatric Disease Designation from the FDA
  • DIPG combination study with OKN-007 and standard of care is planned
  • Oblato granted Fast Track Designation of OKN-007 for Diffuse Intrinsic Pontine Glioma from the FDA
  • Oblato provides OKN-007 as an investigation drug for expanded access use in the United States for patients with diffuse midline glioma (DMG), H3 K27-altered, including DIPG.
§ OKN-007 received Orphan Drug Designation for all malignant gliomas, including GBM and DIPG